Current version snapshot
Current · version 2: GHRP-2↗↗
Related names recorded in this version: Pralmorelin, Growth hormone-releasing peptide 2↗
A synthetic six-amino-acid growth hormone secretagogue, also called pralmorelin, that FDA lists among compounding substances that may present significant safety risks.↗↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test. 576
What this version reported
Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Reader guide in this version
Key takeaway
GHRP-2 (growth hormone-releasing peptide 2) is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name pralmorelin.1 In small human studies it raised growth hormone levels and appetite, and Japanese researchers have tested it as a diagnostic test for adult growth hormone deficiency.6,7 FDA has placed GHRP-2 in category 2 of its 503B compounding list, for substances that may present significant safety risks, citing possible immune reactions and reports of serious adverse events, though causality has not been established. Its 503A nominations list places GHRP-2 in category 3, nominated without adequate support.2,5 No FDA approval is reported in the sources reviewed here, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
At a glance
- What it is
- A synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.2,5
- Human evidence
- A small randomized, placebo-controlled study of growth hormone and appetite, and a diagnostic study comparing people with and without growth hormone deficiency. FDA also reports serious adverse events in patients who received GHRP-2.2,6,7
- Evidence strength
- Smaller controlled human trials
What is GHRP-2?
GHRP-2 is a synthetic peptide of six amino acids, several of them in the unnatural D form, ending in an amide. FDA’s substance registry records it as pralmorelin, growth hormone-releasing peptide 2 and KP-102.1
FDA notes that GHRP-2 contains an unnatural amino acid, which makes the peptide harder to characterize.2
How is GHRP-2 thought to work?
Its registered name, growth hormone-releasing peptide 2, describes its intended action of prompting the release of growth hormone.1
The authors of a 2006 study describe it as a growth hormone secretagogue that acts like ghrelin, a hormone that stimulates appetite, and report that it raised both growth hormone levels and food intake.7
What do human studies show?
In a 2006 double-blind, randomized, placebo-controlled study, 19 healthy lean and obese adults ate more at a buffet meal after GHRP-2 than after placebo: about 10% more at the lower level tested and about 34% more at the higher. Growth hormone rose in all participants.7
In a 2007 Japanese study of 77 healthy people and 58 patients with severe growth hormone deficiency, peak growth hormone after GHRP-2 was far lower in the patients, and the authors proposed a cut-off for diagnosing the deficiency.6
FDA reports being aware of serious adverse events in patients who received GHRP-2, including a greater need for insulin to control blood sugar, deaths of critically ill study participants, infection and pancreatitis, though causality has not been established.2
These studies measured short-term hormone and appetite responses. The sources reviewed here do not show that GHRP-2 is effective or safe as a treatment for any condition.2,6,7
What the evidence base contains
- Controlled human trial A double-blind, randomized, placebo-controlled study in 19 healthy lean and obese adults, each tested on three visits, published in 2006.7
- Small, short, or incompletely reported human study A 2007 Japanese diagnostic study in 77 healthy people and 58 patients with severe growth hormone deficiency, measuring the growth hormone response to GHRP-2.6
- Small, short, or incompletely reported human study Reports, cited by FDA, of serious adverse events in patients who received GHRP-2, including higher insulin needs, deaths of critically ill study participants, infection and pancreatitis, with causality not established.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is GHRP-2 FDA-approved?
None of the sources reviewed here reports an approval of GHRP-2 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.2
FDA’s list of bulk drug substances nominated for pharmacy compounding under section 503A, updated May 14, 2026, places GHRP-2 in category 3: substances nominated without adequate support.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.3,4
Timeline
- Results of a randomized, placebo-controlled study of GHRP-2 and appetite are published.7
- Results of a Japanese study of GHRP-2 as a diagnostic test for adult growth hormone deficiency are published.6
- FDA places GHRP-2 in category 2 under its 503B interim compounding policy, according to its safety-risk page.2
- FDA’s compounding safety-risk page, as last updated, keeps GHRP-2 in category 2.2
- FDA’s 503A nominations list, as last updated, places GHRP-2 in category 3.5
What is still unknown?
Whether it is effective for any condition: the human studies reviewed here measured short-term hormone and appetite responses or tested it as a diagnostic.6,7
Whether the serious adverse events FDA describes were caused by GHRP-2, which FDA states has not been established.2
Sources for this version
- 1Pralmorelin (GHRP-2) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 6A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397 ↗
European Journal of Endocrinology · Official source · Source checked November 16, 2026
- 7Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611 ↗
Obesity · Official source · Source checked November 16, 2026